Research Article
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
Table 4
Adverse events reported in all patients treated with teriflunomide.
| | Teriflunomide, N = 81 |
| Patients with at least one adverse event, n (%) | 66 (81.4%) |
| The proportion of patients with an adverse event, n (%) | Hair thinning (hair loss) | 51 (62.9%) | Nail loss | 17 (20.9%) | Liver dysfunctional test | 12 (14.8%) | Itching | 8 (9.8%) | Nausea | 8 (9.8%) | Pruritus | 5 (6.1%) | Dyspnea | 4 (4.9%) | Diarrhea | 3 (3.7%) | Paresthesia | 3 (3.7%) | Headache | 2 (2.5%) | Psychiatric disorder | 2 (2.5%) | Mediastinitis | 1 (1.2%) | Flushing | 1 (1.2%) | Abdominal pain | 1 (1.2%) | Urinary tract infection | 1 (1.2%) | Recurrent urinary tract infection | 1 (1.2%) | Dry mouth | 1 (1.2%) | Eye disorder | 1 (1.2%) |
|
|